Clinical Trials Logo

Clinical Trial Summary

Sexuality is a high rehabilitative priority for persons following a spinal cord injury (SCI). Sexual acts can lead to autonomic dysreflexia (AD), dangerous consequences such as a sudden increase in blood pressure, severe headache, sweating above the level of the lesion and low heart rate to name a few. Ejaculation in men can provoke these significant symptoms and therefore men and women may refrain from a sexual life and biological parenthood. Adalat is the most common antihypertensive used in fertility clinics to reduce the incidence of AD. It dramatically reduces blood pressure and, therefore, results in side effects such as dizziness, fatigue and weakness. The investigators hypothesize that Minipress® (prazosin HCL), a blood pressure medication, which has a slower and less abrupt suppressive effect on blood pressure, would be a safe, effective and more appropriate medication for use in the outpatient sperm retrieval clinic and potentially for private use.


Clinical Trial Description

The consequences of sexual activity in the spinal cord injured (SCI) population include responses beyond the voluntary control of the person with SCI such as bladder and bowel issues, spasms and autonomic dysreflexia (AD). Currently we are looking at predictive measurements for AD during ejaculation in a controlled setting. Immediate-release Nifedipine (Adalat), a well-known medication used for the treatment of AD is the most commonly prescribed prophylactic antihypertensive used in sperm retrieval and urological procedures. Nifedipine has rapid onset (minutes) and dramatically lowers blood pressure for periods of up to five hours and results in dizziness, fatigue and weakness. As a sperm retrieval center not equipped for hypotensive resuscitation measures, we have refrained from using Nifedipine prior to procedures in hypotensive SCI men at risk for AD.

Our objective is to study the prophylactic capacity of a lesser prescribed antihypertensive medication Prazosin on its ability to reduce the objective and subjective measures of autonomic dysreflexia in order to assess its immediate potential for home use. Prazosin is an alpha-adrenergic blocker and has a slower and less abrupt suppressive effect on blood pressure. We hypothesize that it will reduce AD signs and symptoms, reduce the severity of cardiovascular changes, and improve client comfort without reduction in safety. Having 8 male subjects as their own controls, we plan to examine the objective (beat to beat blood pressure, EKG and visible body signs) and subjective (patient's symptomatic report) parameters of AD provoked by vibrostimulation and ejaculation on and off Minipress (Prazosin HCL). Statistical analysis will be done on three independent observations:

1. absolute blood pressure values and reduction in abnormal heart rhythms

2. signs and symptoms of AD

3. client confidence to undergo ejaculation

We will correlate objective parameters with the subjective findings to see if these observations can be predictive in determining the predictability and severity of AD and the effectiveness of Prazosin as prophylactic AD medication in an outpatient clinic or a private home setting during sexual activities. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT00175682
Study type Interventional
Source University of British Columbia
Contact
Status Completed
Phase N/A
Start date December 2004
Completion date July 28, 2011

See also
  Status Clinical Trial Phase
Not yet recruiting NCT05635851 - NO AD: Use of Nitric Oxide (NO) Donors for the Prevention of Autonomic Dysreflexia (AD) During Bowel Care Following SCI Phase 2
Recruiting NCT05351827 - Mild Intermittent Hypoxia: A Prophylactic for Autonomic Dysfunction in Individuals With Spinal Cord Injuries N/A
Completed NCT03307161 - Osteopathic Manual Treatment Parkinson's Disease and Truncal Dystonia N/A
Recruiting NCT04493372 - Deciphering Preserved Autonomic Function After Spinal Cord Injury N/A
Not yet recruiting NCT06211491 - Autonomic Dysreflexia in Spinal Cord Injuries: UDS Filling Speed Impact
Completed NCT02919917 - Treatment of Post-SCI Hypotension Phase 2/Phase 3
Recruiting NCT05380661 - Heart Rate Variability and Anxiety During Urinary Bladder Catheterization N/A
Recruiting NCT04193709 - Recovery of Bladder and Sexual Function After Human Spinal Cord Injury N/A
Recruiting NCT05024487 - Prevention of Complications Due to Autonomic Dysreflexia in SCI Individuals N/A
Completed NCT02676154 - Fesoterodine for Amelioration of Autonomic Dysreflexia (AD) Following Spinal Cord Injury (SCI) Phase 2
Completed NCT04858178 - Transcutaneous Spinal Cord Neuromodulation to Normalize Autonomic Phenotypes N/A
Not yet recruiting NCT03924388 - Spinal Cord Stimulation and Autonomic Response in People With SCI. N/A
Completed NCT02893553 - The Effects of Normalizing Blood Pressure on Cerebral Blood Flow in Hypotensive Individuals With Spinal Cord Injury Phase 2
Completed NCT02006433 - Treatment of Pain and Autonomic Dysreflexia in Spinal Cord Injury With Deep Brain Stimulation N/A
Completed NCT02298660 - Botox for Neurogenic Detrusor Overactivity and the Prevention of Autonomic Dysreflexia Following SCI Phase 4